InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Cover Story

  • Your step-by-step guide to IP lobbying

    As IP issues move up the political agenda IP owners and their lawyers have their biggest opportunity yet to influence the policy making process. Emma Barraclough and Eileen McDermott explain how to do it

  • A history of IP lobbying

    Managing IP profiles some of the most heavily lobbied IP issues worldwide and considers how IP owners and activists shaped the debate - and the outcome

  • Avoid a PR disaster in Asia

    IP lobbying extends to more than just official policy making. Peter Ollier looks at how companies can ensure that their voice is heard during litigation in Asia

Features

IP Clinic

  • How do we stop lookalikes?

    Our company launched a new product last year but we have since discovered that a leading supermarket is selling an own brand version that looks very similar. What should we do?

Diary

  • Utynam's Heirs

    A monthly column devoted to IP curiosities and controversies, named in honour of John of Utynam - who received the world's first recorded patent in 1449

Country Updates

profile

Managing IP

ManagingIP

ManagingIP profile

ICYMI: Our report on this week's #SCOTUS ruling in Star Athletica v Varsity Brands https://t.co/Rf3TWplNUrhttps://t.co/TrZ5YcvKQr

Mar 24 2017 01:35 ·  reply ·  retweet ·  favourite
ManagingIP profile

@Oblon_IP @PatentPostGrant Congratulations Scott! #mipawards

Mar 24 2017 01:13 ·  reply ·  retweet ·  favourite
ManagingIP profile

@KellyIPllp Well done to all at the firm!

Mar 24 2017 02:16 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


March 2017

Roundtable: The second medical use challenge – full transcript

Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London



Most read articles

Supplements